Helsinn appoints Giacomo Braglia to the Board of Directors
Lugano, Switzerland – April 16th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, is pleased to announce the appointment of Giacomo Braglia as a new member of its Board of Directors, effective immediately.
Giacomo Braglia currently serves as Business Development Manager and Marketing and Communications Manager at HAS Healthcare Advanced Synthesis, a pharmaceutical company controlled by the Braglia Family, where he is also a member of the Board of Directors. His appointment to the Board of Helsinn further reinforces the Braglia Family’s continued commitment to shaping Helsinn’s long-term development and supporting the company’s vision for sustained success in the years ahead.
Giacomo holds a Bachelor in Global Business Management from Regent’s University London and a Master’s Degree in International Marketing from Hult International Business School in London.
Riccardo Braglia, Chairman and CEO of Helsinn, commented: “As a family-owned company, Helsinn has always been guided by a long-term vision. I am pleased to welcome my son, Giacomo, to our Board of Directors. His fresh perspective and forward-looking mindset will be a valuable contribution as we continue to strengthen Helsinn’s long-term development and advance our mission of supporting patients living with cancer and chronic diseases.”
Helsinn’s Board of Directors now comprises:
- Riccardo Braglia - Chairman of the Board of Directors
- Eric Cornut - Vice-Chairman of the Board of Directors; Audit & Risk Committee (ARC) Member; Nomination & Compensation Committee (NCC) Chairman
- Paolo Bottini - Board Member; ARC Chairman
- Riccardo Carbucicchio - Board Member; NCC Member
- Gabriele Edoardo Braglia - Board Member; ARC Member
- Giacomo Braglia - Board Member
About Helsinn
Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic diseases, with a focus on supportive care, oncology and dermato-oncology. Headquartered in Lugano, Switzerland, Helsinn has direct commercial operations in the U.S., manufacturing operations in Ireland, offices in China, and a network of trusted partners enabling a commercial presence in 90 countries.
Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. For half a century, Helsinn has been operating with integrity, passion, and quality. The company continuously fosters innovation for its patients and embraces sustainable growth as a core element of its strategic vision.
To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X.
For more information:
Helsinn Media Contact
Sabrina Perucchi
Group Communication Manager
Tel: +41 (0) 91 985 21 21
Email: communications@helsinn.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
